FASLODEX Overview

FASLODEX Mechanism of Action 

FASLODEX Is An Estrogen Receptor Antagonist1,2 

Many breast cancers have estrogen receptors, and the growth of these tumors can be stimulated by estrogen.1 See how FASLODEX blocks estrogen binding and inhibits estrogen-stimulated cell division.1-4 

Target the Estrogen Receptor (ER) with FASLODEX

Watch the FASLODEX MOA Video

This content is not currently available for your device.

X


1751106-2951300 Last Updated 5/14

INDICATION FOR FASLODEX:

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

IMPORTANT SAFETY INFORMATION:

FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.

Read more

Important Safety Information About FASLODEX

  • FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX

  • Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants

  • FASLODEX is metabolized primarily in the liver. A 250-mg dose is recommended in patients with moderate hepatic impairment. FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh Class C)

  • Fetal harm can occur when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant while receiving FASLODEX

  • The most common, clinically significant adverse reactions occurring in ≥5% of patients receiving FASLODEX were: injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, vomiting, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, and constipation

  • Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of FASLODEX users and were non dose-dependent

Indication For FASLODEX

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Prescribing Information with Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1‑800‑FDA‑1088.

*CONFIRM = COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer.

References:

  1. FASLODEX full Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  2. Howell A. Is fulvestrant (“Faslodex”) just another selective estrogen receptor modulator? Int J Gynecol Cancer. 2006;16(2):521-523.
  3. Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer. 2005;6(suppl 1):S5-S8.
  4. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7(1):17-28.